Protection from Reperfusion Injury with Intracoronary N -Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center
ConclusionsIn this study, NAC improved myocardial reperfusion markers and coronary blood flow, as revealed by differences in peak hs-TnT and TIMI flow grade 3 levels, respectively. Further studies with large samples are warranted to elucidate the role of NAC in this population.ClinicalTrials.gov identifier: NCT01741207, and the Iranian Registry of Clinical Trials (IRCT;http://irct.ir) registration number: IRCT201301048698N8.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Acetylcysteine | Angioplasty | Antidoxidants | Cardiology | Cardiovascular | Clinical Trials | Coronary Angioplasty | Heart | Heart Attack | Iran Health | Percutaneous Coronary Intervention | Study